Clinical Trial: 22018

Trial Status: Open
Disease Type: Breast
Trial ID 22018
Sponsor ID Genentech

A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Principal Investigator
Anne Favret, MD
3 Locations

Locations

Arlington Office

Fairfax Office

Gainesville Office

Learn More About This Trial

Other Relevant Trials
Trial ID 21380
Sponsor ID post-MONARCH

postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Principal Investigator
Anne Favret, MD
3 Locations
Trial ID 21234
Sponsor ID ARTEST

(V3002401) ARTEST – A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with Androgen Receptor Nuclei Staining greater than or equal to 40% Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK…

Principal Investigator
Anne Favret, MD
3 Locations